Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 376
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. William J. Sibold | CEO, President & Director | 1.67M | N/D | 1966 |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 928.11k | N/D | 1952 |
| Ms. Carole Huntsman | Chief Commercial Officer | 94k | N/D | 1965 |
| Ms. Mardi C. Dier | CFO & Senior VP | N/D | N/D | 1964 |
| Mr. Ronald Filippo | Chief Information Officer | N/D | N/D | N/D |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | N/D | N/D | N/D |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel | N/D | N/D | N/D |
| Mr. Clint Wallace | Chief Human Resources Officer | N/D | N/D | N/D |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/D | N/D | N/D |
| Mr. Thomas W. Hare | Senior Vice President of Clinical Management | N/D | N/D | N/D |
Descripción
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Madrigal Pharmaceuticals, Inc. a partir del 1 de octubre de 2024 es 7. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 8; Compensación: 8.
